AstraZeneca and Daiichi Sankyo will talk to regulators about their promising new Phase III results for datopotamab deruxtecan (Dato-DXd) in the most common form of advanced breast cancer – but may have to hold on for overall survival results before filing.
The companies have revealed that the TROP2-targeted antibody-drug conjugate (ADC) hit its primary endpoint of progression-free survival (PFS) in the...